Connect with us

Bristol-Myers licenses potential leukemia therapy developed at Moffitt

January 13, 2020 - ANP Technologies Inc.  and Fulgent Pharma LLC, through their partner Moffitt Cancer Center, have successfully licensed the rights to develop a novel targeted therapy in the area of leukemia to Celgene, recently acquired by Bristol-Myers Squibb (NYSE: BMY). Financial terms of the licensing agreement were not disclosed. The partners will work together to develop a new cancer therapy for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), a news release said. 

More Zaps Frontpage

The St. Pete Catalyst

The Catalyst honors its name by aggregating & curating the sparks that propel the St Pete engine.  It is a modern news platform, powered by community sourced content and augmented with directed coverage.  Bring your news, your perspective and your spark to the St Pete Catalyst and take your seat at the table.

Email us:

Subscribe for Free

Share with friend

Enter the details of the person you want to share this article with.